1. Overall and disease-specific survival of sinonasal adenoid cystic carcinoma: a systematic review and meta-analysis.
- Author
-
Mauthe T, Holzmann D, Soyka MB, Mueller SA, Balermpas P, Held U, Freiberger SN, Rupp NJ, and Meerwein CM
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Carcinoma, Adenoid Cystic pathology, Carcinoma, Adenoid Cystic radiotherapy, Paranasal Sinus Neoplasms therapy, Paranasal Sinus Neoplasms pathology, Nose Neoplasms pathology, Frontal Sinus pathology
- Abstract
This meta-analysis aims to investigate the outcome of sinonasal adenoid cystic carcinoma (snAdCC). We followed PRISMA guidelines and included studies reporting 5-year overall survival (OS) rates for snAdCC. Eligible studies were identified through a literature search and assessed using JBI critical appraisal checklist. A total of 17 studies were included comprising 2259 patients (mean age: 58.1 years, 52.7% female, 47.3% male). The meta-analysis demonstrated that the 5-year OS, 10-year OS, and 5-year disease-free survival (DFS) were 68%, 40%, and 47.2%, respectively. Descriptive statistics on study level showed high rates of locally advanced tumor stages at diagnosis: 23% cT3, 53% cT4, 3.4% N+, and 4.2% M+. 29.7% of the tumors were in the nasal cavity, 67.6% in the paranasal sinuses. The maxillary, ethmoid, sphenoid, and frontal sinus were affected in 50.9%, 7.2%, 4%, and 0.5%, of cases. A combination of surgery and radiotherapy was used in 45.4% of the patients and 19.3% of patients received surgery only. In conclusion, these findings emphasize the significance of thorough surveillance for individuals with snAdCC to identify any potential recurrence or progression of the disease.
- Published
- 2023
- Full Text
- View/download PDF